Lifeboat Foundation

For instance, the pegRNA molecules used in prime editing are difficult and expensive to chemically synthesise or laborious to clone, which hampers the crucial optimisation of prime-editing efficiency. Additionally, the reverse transcriptase (RT) enzymes used in prime editing are relatively error-prone and have low processivity, which may limit the precision and size of edits that can be introduced. Furthermore, RTs have a low affinity for dNTPs, which can impact prime-editing efficiency in non-dividing and differentiated cells.

To address these issues, two research groups led by Dr. Ben Kleinstiver at Mass General Hospital (MGH) & Harvard Medical School, and Dr. Erik Sontheimer at the RNA Therapeutics Institute (UMass Chan Medical School) have independently developed new approaches that build upon prime editing by replacing RT with another type of enzyme, namely a DNA-dependent DNA polymerase. This change permits the use of DNA instead of RNA as a template for editing, potentially addressing some of the main limitations of prime editing by allowing higher efficiency and adaptability.

A “chaperone” molecule that slows the formation of certain proteins reversed disease signs, including memory impairment, in a mouse model of Alzheimer’s disease, according to a study from researchers at the Perelman School of Medicine at the University of Pennsylvania.

In the study, published in Aging Biology, researchers examined the effects of a compound called 4-phenylbutyrate (PBA), a fatty-acid molecule known to work as a “chemical chaperone” that inhibits protein accumulation. In mice that model Alzheimer’s disease, injections of PBA helped to restore signs of normal proteostasis (the protein regulation process) in the animals’ brains while also dramatically improving their performance on a standard memory test, even when administered late in the disease course.

“By generally improving neuronal and cellular health, we can mitigate or delay disease progression,” said study senior author Nirinjini Naidoo, Ph.D., a research associate professor of Sleep Medicine. “In addition, reducing proteotoxicity— irreparable damage to the cell that is caused by an accumulation of impaired and misfolded proteins—can help improve some previously lost brain functions.”

Neurons communicate through chemical signals known as neurotransmitters. Researchers at St. Jude Children’s Research Hospital, leveraging their expertise in structural biology, have successfully elucidated the structures of the vesicular monoamine transporter 2 (VMAT2), a key component of neuronal communication.

By visualizing VMAT2 in different states, scientists now better understand how it functions and how the different shapes the protein takes influence drug binding — critical information for drug development to treat hyperkinetic (excess movement) disorders such as Tourette syndrome. The work was recently published in the journal Nature.

Groundbreaking research reveals new details about water vapor’s interaction with metals at an atomic level, with implications for corrosion management and clean-energy development.

When water vapor meets metal, the resulting corrosion can lead to mechanical problems that harm a machine’s performance. Through a process called passivation, it also can form a thin inert layer that acts as a barrier against further deterioration.

Either way, the exact chemical reaction is not well understood on an atomic level, but that is changing thanks to a technique called environmental transmission electron microscopy (TEM), which allows researchers to directly view molecules interacting on the tiniest possible scale.

A non-organic intelligent system has for the first time designed, planned and executed a chemistry experiment, Carnegie Mellon University researchers report in the Dec. 21 issue of the journal Nature.

“We anticipate that intelligent agent systems for autonomous scientific experimentation will bring tremendous discoveries, unforeseen therapies and new materials. While we cannot predict what those discoveries will be, we hope to see a new way of conducting research given by the synergetic partnership between humans and machines,” the Carnegie Mellon research team wrote in their paper.

Continue reading “Artificially intelligent ‘Coscientist’ automates scientific discovery” »

“Coscientist” AI checks references, reads hardware manuals, and sets up reactions.

In quantum mechanics, particles can exist in multiple states at the same time, defying the logic of everyday experiences. This property, known as quantum superposition, is the basis for emerging quantum technologies that promise to transform computing, communication, and sensing. But quantum superpositions face a significant challenge: quantum decoherence. During this process, the delicate superposition of quantum states breaks down when interacting with its surrounding environment.

To unlock the power of chemistry to build complex molecular architectures for practical quantum applications, scientists need to understand and control quantum decoherence so that they can design molecules with specific quantum coherence properties. Doing so requires knowing how to rationally modify a molecule’s chemical structure to modulate or mitigate quantum decoherence.

To that end, scientists need to know the “spectral density,” the quantity that summarizes how fast the environment moves and how strongly it interacts with the quantum system.

“Even now, quantum systems can serve as scientific tools,” Oliver Dial, IBM Quantum CTO told IE in an interview. Quantum utility might already be here, but will we soon see a company achieve quantum advantage?

But what exactly does that mean?

Continue reading “IBM’s Quantum System Two will help it unlock the ‘full power of quantum computing’” »

DNA is the building block of life, and the genetic alphabet comprises just four letters or nucleotides. These biochemical building blocks comprise all types of DNA, and scientists have long wondered whether creating working artificial DNA would be possible. Now, a breakthrough may finally provide the answer.

The main goal of a new study, the findings of which were published in Nature Communications this month, shows that scientists may finally be able to create new medicines for certain diseases by creating DNA with new nucleotides that can create custom proteins.

Being able to create artificial DNA could open the door for several important uses. Being able to expand the genetic code could very well diversify the “range of molecules we can synthesize in the lab,” the study’s senior author Dong Wang, Ph.D., explained (via Phys.org).